| Bioactivity | ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with Ki values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease[1]. |
| Target | Ki: 79.6 nM (FIH); 2786 nM (PHD2) |
| In Vivo | ZG-2305 能够恢复饮食诱导的肥胖雄性小鼠的异常体重和肝脏脂肪变性，并改善 HF-CDAA (胆碱缺乏的 L-氨基酸定义为高脂肪) 饮食诱导的 NASH 小鼠模型中的 NASH (非酒精性脂肪性肝炎) 相关的肝损伤、脂肪变性、炎症和纤维化[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Formula | C17H11Cl2N3O5 |
| Molar Mass | 408.19 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wu Y, et al. Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver Disease. J Med Chem. 2024 Oct 21. |